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Selenium supplementation to improve bone health in
postmenopausal women: the SeMS three-arm RCT
Jennifer S Walsh ,1* Richard Jacques ,2 Lutz Schomburg ,3 Tom Hill,4
John Mathers ,4 Graham Williams 5 and Richard Eastell 1
1Mellanby Centre for Bone Research, University of Sheffield, Northern General Hospital, Sheffield, UK
2School of Health and Related Research, University of Sheffield, Sheffield, UK
3Institut für Experimentelle Endokrinologie, Berlin, Germany
4Human Nutrition Research Centre, Newcastle University, Newcastle upon Tyne, UK
5Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
*Corresponding author j.walsh@sheffield.ac.uk
Background: Observational and pre-clinical studies have reported an association between selenium
status, bone density, bone turnover and fracture risk. Selenium is an anti-oxidant, so we hypothesised
that selenium could reduce the pro-resorptive action of reactive oxygen species on osteoclasts.
Population mortality data suggest that the optimum range for serum selenium is 120–150 µg/l.
Most adults in Europe are relatively selenium insufficient compared with adults in the USA and other
geographical areas.
Objectives: The objectives of the study were to determine if selenium supplementation in
postmenopausal women with osteopenia decreased bone turnover, improved physical function or
decreased markers of oxidative stress and inflammation.
Design: We conducted a 6-month double-blind, randomised, placebo-controlled trial.
Setting: This was a single-centre study in Sheffield, UK.
Participants: We recruited 120 postmenopausal women with osteopenia or osteoporosis. One hundred
and fifteen women completed follow-up and were included in the intention-to-treat analysis.
Interventions: The interventions were sodium selenite as Selenase 200 µg/day, Selenase 50 µg/day
(biosyn, Germany) and placebo.
Main outcome measures: The primary end point was urine N–terminal cross-linking telopeptide of
type I collagen/Cr (NTX/Cr) at 26 weeks. Groups were compared with an analysis of covariance, through
the use of Hochberg testing. Secondary end points were other biochemical markers of bone turnover,
bone mineral density by dual-energy X-ray absorptiometry and physical function scores (short physical
performance battery and grip strength). The mechanistic end points were markers of inflammation and
anti-oxidant activity (glutathione peroxidase, highly sensitive C-reactive protein and interleukin 6).
Results: In the 200 µg/day group, mean serum selenium increased from 78.8 µg/l (95% confidence
interval 73.5 to 84.2 µg/l) to 105.7 µg/l (95% confidence interval 99.5 to 111.9 µg/l) at 26 weeks. Urine
NTX/Cr did not differ between treatment groups at 26 weeks. None of the secondary or mechanistic
end-point measurements differed between the treatment groups at 26 weeks.
Conclusions: We conclude that selenium supplementation at these doses does not affect bone turnover
(assessed by NTX/Cr) and is not beneficial for musculoskeletal health in postmenopausal women.
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v
Trial registration: IRAS 200308, EudraCT 2016-002964-15 and ClinicalTrials.gov NCT02832648.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme,
a MRC and National Institute for Health Research (NIHR) partnership. This will be published in full
in Efficacy and Mechanism Evaluation; Vol. 8, No. 6. See the NIHR Journals Library website for further
project information.
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BCE bone collagen equivalents
BMD bone mineral density
BMI body mass index
CI confidence interval
CTX C–terminal cross-linking
telopeptide of type I collagen
CV coefficient of variation
DMC Data Monitoring Committee
DXA dual-energy X-ray absorptiometry
HbA1c glycated haemoglobin
HRT hormone replacement therapy
hsCRP highly sensitive C-reactive protein
IL-6 interleukin 6
IMP Investigational Medical Product
ITT intention to treat
NTX N–terminal cross-linking
telopeptide of type I collagen
OC osteocalcin
PINP procollagen type I N propeptide
REC Research Ethics Committee
SAE serious adverse event
SAP statistical analysis plan
SD standard deviation
SePP selenoprotein P
SERM selective oestrogen receptor
modulator
SPPB short physical performance battery
TSC Trial Steering Committee
TSH thyroid-stimulating hormone
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Osteoporosis is a major public health problem. One in two women and one in five men over the ageof 50 years will have a fracture. Fractures cause pain and disability and reduce life expectancy. There
are effective medications for osteoporosis, but some people prefer not to take them because of concerns
about possible side effects. Selenium is a nutrient that forms part of several important human biological
processes, including anti-oxidants. Anti-oxidants may protect against the ageing of tissues, including bone,
by mopping up damaging reactive oxygen molecules (sometimes called ‘free radicals’). Selenium is present
in soil, and therefore it is obtained from many foods. However, soil selenium levels are low in Europe, and
dietary intake in the UK is below recommended levels. We previously found that women with higher blood
selenium levels have stronger bones, so we proposed that giving selenium supplements could improve
bone and muscle health.
We conducted a randomised double-blind placebo-controlled trial to compare selenium supplements
with a placebo (dummy treatment) in postmenopausal women with below-average bone density.
We gave selenium (at two different doses) or placebo once a day to 120 women for 6 months and
measured the effects with blood and urine tests, bone density scans and muscle strength tests. After
6 months of treatment, selenium supplements did not have any effect on bone or muscle. We conclude
that selenium supplements at these doses are not likely to be effective for treatment of osteoporosis
and reduction in fracture risk in postmenopausal women.
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About 30% of women aged > 65 years have osteopenia (bone mineral density T-score of –1.0 to –2.5).
These women are at increased risk of fracture and are likely to develop osteoporosis, but their bone
mineral density is not low enough for osteoporosis treatment such as bisphosphonates. Previously, these
women may have been offered hormone replacement therapy as a bone protective measure, but adverse
events have reduced the use of hormone replacement therapy, so there is a large unmet clinical need.
Selenium is a chemical element present in several human enzymes regulating the pathways for synthesis of
thyroid hormones, and in anti-inflammatory and anti-oxidant proteins. Large-scale population data show
that selenium status is associated with all-cause mortality and that the optimum range of serum selenium
for human health is around 120–150 µg/l. Selenium status is suboptimal in the UK; average serum selenium
is about 85 µg/l. Anti-oxidant selenoproteins reduce interleukin 6 and reactive oxygen species, both of
which are potent stimuli for osteoclast bone resorption.We have previously published a European study
showing that plasma selenium is associated with bone mineral density and bone turnover in a population-
based sample of older women. There are also data to suggest associations with muscle function and
strength. Subsequent studies by other groups have reported associations between selenium status, bone
mineral density and fracture risk.
We hypothesised that selenium supplementation would reduce bone resorption in postmenopausal
women through reduced reactive oxygen species. If effective, selenium supplements could be a safe,
inexpensive and easily available bone health intervention, and would be attractive to patients because
it is perceived as a ‘natural’ treatment. The potential adverse effects of selenium supplementation are
thyroid dysfunction (because selenium is present in thyroid hormone synthesis enzymes) and increased
risk of diabetes (from population studies of selenium status but not confirmed by any of the previous
randomised supplementation trials).
Objective
The objective was to determine if selenium supplementation in postmenopausal women improved bone
health or muscle function.
Methods
We conducted a 6-month double-blind, randomised, placebo-controlled trial of selenium supplementation
in 120 postmenopausal women in the UK. The interventions were sodium selenite as Selenase 200 µg/day,
Selenase 50 µg/day (biosyn, Germany) and placebo. We chose a dose of 200 µg/day because this dose
has shown to be effective for treatment of Graves’ eye disease and in some cancer prevention studies.
In addition, we estimated that this dose would increase serum selenium to about 120 µg/l. The primary
end point was urine N–terminal cross-linking telopeptide of type I collagen/Cr (NTX/Cr), which is a
biochemical marker of bone resorption. We used a biochemical marker as the primary end point because
biochemical markers are proven to predict bone mineral density change and fracture risk reduction
with osteoporosis treatment. Furthermore, biochemical markers change much more quickly than bone
mineral density. We chose NTX/Cr as the primary end point because it was the marker that was most
strongly correlated with serum selenium in our previous study. Secondary end points were other
biochemical markers of bone turnover (procollagen type I N propeptide, C-terminal cross-linking
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telopeptide of type I collagen and osteocalcin), bone mineral density by dual-energy X-ray absorptiometry
and physical function scores (short physical performance battery and grip strength). Mechanistic end
points were markers of inflammation and anti-oxidant activity (glutathione peroxidase, highly sensitive
C-reactive protein and interleukin 6). Safety end points were symptoms of selenium toxicity, thyroid
function, blood glucose and glycated haemoglobin. The study had 90% power to detect a 20% between-
group difference (approximately 10 nmol BCE/mmolCr) in NTX/Cr. The mean NTX/Cr between the groups
was compared with an analysis of covariance, adjusting for baseline NTX/Cr. The primary analysis was by
intention to treat.
The study recruited to target, and the study was conducted and analysed according to the protocol
and statistical analysis plan. The only deviation from the original plan was that we did not make the
planned measurement of hydroperoxidases because the commercial assay we planned to use was
withdrawn before the study was complete.
Results
In the 200 µg/day group, mean serum selenium increased from 78.8 µg/l to 105.7 µg/l. Urine NTX/Cr did
not differ between treatment groups at 26 weeks. None of the secondary or mechanistic end points
differed between treatment groups at 26 weeks. The number and type of adverse events were similar
between groups.
Conclusions
We conclude that selenium supplementation at these doses does not affect bone turnover (assessed by
NTX/Cr) and is not beneficial for musculoskeletal health in postmenopausal women.
Trial registration
This trial is registered as IRAS 200308, EUDRACT 2016-002964-15 and Clinicaltrials.gov NCT02832648.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and National
Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism
Evaluation; Vol. 8, No. 6. See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Parts of this report are based on Walsh et al.
1 © 2021 The Authors. Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license.
One in two women and one in five men aged > 50 years will have a fragility fracture. Fractures lead to
pain, disability, loss of independence and increased mortality. This is a huge health burden for affected
individuals, the NHS and social care, and it is increasing as the population ages.
About 30% of women aged > 65 years are osteopenic (i.e. they have below-average bone density) and
are at risk of developing osteoporosis and fractures. More than 50% of all fractures in postmenopausal
women occur in those with osteopenia. These women are generally not given osteoporosis treatment
at present because of the individual risk–benefit ratio. Previously, these women could have been offered
hormone replacement therapy (HRT) for bone protection, but adverse effects of HRT have limited its use.
Bisphosphonates are the mainstay of osteoporosis treatment for women at higher risk, but use of these
medications has declined because of physician and patient wariness of adverse events.2 More costly
treatments, such as teriparatide and denosumab, are restricted to patients with more severe osteoporosis
who do not respond to bisphosphonate treatment. Calcium and vitamin D supplements are generally
recommended for osteopenic adults, but effects on bone density are small and may not outweigh the risk
of adverse effects.3
Therefore, there is a need for an effective, safe, well-tolerated, inexpensive and widely applicable
preventative option for osteopenic women.
Selenium is a chemical element present in several human proteins. Twenty-five human selenoproteins
have been identified.4 Known functions of selenoproteins include thyroid hormone synthesis
(iodothyronine deiodinases) and anti-oxidants (thioredoxin reductases and glutathione peroxidases).5,6
Selenoproteins are anti-inflammatory and anti-oxidant; they reduce levels of interleukin 6 (IL-6) and
reactive oxygen species, both of which are potent stimuli for bone resorption.7–10
Selenium is obtained from diet, particularly seafood, meat and cereals. The main determinant of food
selenium content is soil selenium content. The recommended adequate intake for adults aged > 50 years in
the UK is 75 µg/day for men and 60 µg/day for women,11 but in the UK the mean intake is only 40 µg/day.12
Selenium intakes have been declining in the UK in the past few decades and are generally low in Europe
compared with the USA. The main reason for the decreasing intake in the UK is a change in the source of
flour for bread-making from North America (which contains higher selenium) to Europe. More recently, the
levels of selenium in UK soils have declined because of changes in fertiliser practice (e.g. replacing single
superphosphate with triple superphosphate) and reduced industrial emissions.13
Studies of all-cause mortality suggest that the optimum range of serum selenium for human health is
between about 120 and 150 µg/l. Most adults in the UK have serum selenium between 80 and 100 µg/l.12
We previously reported that, in 1144 older women from the UK, France and Germany, higher serum
selenium or selenoprotein P (SePP) was associated with higher bone mineral density of the lumbar
spine and total hip, and lower biochemical markers of bone turnover.14 High bone turnover is the
principal mechanism of osteoporotic bone loss. We also noted associations of selenium levels with
balance and grip strength. Selenium status was inversely related to thyroid hormone status (selenium is
required for thyroid hormone synthesis), but the associations of selenium with bone measures were
independent of thyroid hormones.
It is plausible that selenium could affect bone metabolism. Selenoproteins are expressed in osteoblasts
and osteoclasts, and are found in the bone microenvironment.7,15 Selenoproteins are anti-inflammatory
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and reduce IL-6, a potent stimulus for bone resorption.8 Selenoproteins are anti-oxidant and reduce
reactive oxygen species; these also stimulate bone resorption via increased RANK-L signalling.15
Oxidative stress markers are associated with high bone resorption markers and lower bone mineral
density (BMD).16,17 An increase in reactive oxygen species has been proposed as a key mechanism by
which sex hormone deficiency causes age-related bone loss through the same RANK pathway.18
Therefore, it is possible that selenium could directly antagonise the cellular mechanism of
postmenopausal osteoporosis.
There is experimental animal evidence to support the hypothesis that selenium has a role in bone
biology and reduces bone turnover. Selenium-deficient mice have poorer bone microarchitecture,
higher bone resorption markers and higher inflammatory markers than selenium supplemented mice.19
Selenium-deficient rats have poor bone microarchitecture and abnormal skeletal growth.20,21
Selenium status has also been associated with BMD in men in the Netherlands,22 and higher selenium intake
was associated with lower hip fracture risk in older adults in the USA,23 but there was no association with
BMD in postmenopausal Turkish women.24 In a US study of hip fracture risk in women aged ≥ 65 years, the
counties that had the highest rates were those situated in a belt across the south of the USA, and the lowest
rates were in the north.25 By contrast, a current map of soil selenium content in the USA shows that the
highest level of selenium content is in the north of the USA and the lowest level is in a belt across the south
of the USA (http://mrdata.usgs.gov/geochem/doc/averages/se/usa.html; accessed 5 February 2021).
Endemic selenium deficiency in humans has been associated with the osteoarthropathy
Kashin–Beck disease.26
Several other age-related disorders are linked to inadequate selenium status, including poor cognitive
function and reduced muscle strength.27 Selenium may be an independent predictor of mortality
among older community-dwelling adults.28 Selenium supplementation with coenzyme Q10 reduced
cardiovascular mortality and markers of inflammation, increased IGF-1 (insulin-like growth factor 1)
and altered microRNA expression in older Swedish adults.29–31 In the Nutritional Prevention of Cancer
trial, selenium supplementation reduced all-cancer risk in people with lower baseline serum selenium,32
and meta-analyses generally find a beneficial effect of selenium on cancer risk.12
The possible adverse effects of selenium supplementation are thyroid dysfunction (because some
selenoproteins are involved in thyroid hormone synthesis) and increased risk of type 2 diabetes mellitus.33
We hypothesised that, in a relatively selenium-deficient population such as the UK, selenium
supplementation would decrease bone turnover by reducing the action of reactive oxygen species on
osteoclast activity and may improve muscle function. In the longer term, both of these actions could
have benefits with regard to reducing fracture risk.
The aim of the study was to determine if selenium supplementation is beneficial for bone health and
muscle function in postmenopausal women.
The objectives of the study were to determine if selenium supplementation in postmenopausal women
with osteopenia:
l decreases bone turnover
l improves physical function score and grip strength
l is safe (particularly for thyroid function and diabetes)
l decreases markers of oxidative stress and inflammation.
INTRODUCTION




We conducted a 6-month randomised, double-blind, placebo-controlled study of selenium
supplementation in 120 postmenopausal women with osteopenia and osteoporosis (see Appendix 1).
The interventions were sodium selenite tablets Selenase 50 µg and 200 µg (biosyn, Germany) and
placebo. The tablets were overencapsulated and a matching placebo was manufactured to maintain
the blind (Sharp Clinical Services, UK). We chose a dose of 200 µg because this dose has previously
been shown to be effective in the Nutritional Prevention of Cancer trial and in treatment of Graves’
ophthalmopathy. We estimated that this dose would increase serum selenium by about 60 µg/l.
The 50 µg dose was included to assess dose response; if 50 µg and 200 µg had similar effects, we could
recommend the 50 µg dose for clinical use, at a lower cost and with a lower risk of adverse effects.
The primary end point was a between-group difference in urine N–terminal cross-linking telopeptide of
type I collagen (NTX)/Cr at 26 weeks.
Bone turnover markers change much more rapidly than BMD, so we can determine quickly and
cost-effectively if an intervention is likely to work. We chose NTX because the relationship between
change in NTX and change in fracture risk is well described with bisphosphonates:34 a 30% decrease
reduction at 3 years is explained by change in NTX. In addition, NTX was the marker mostly strongly
related to selenium status in our observational study.14
The secondary end points were as follows:
l Change in serum selenium, SePP: systematic review identified blood selenium and SePP as robust
biomarkers of selenium status, over the range of deficiency to repletion.35
l Change in other bone turnover markers: procollagen type I N propeptide (PINP), osteocalcin (OC)
and C–terminal cross-linking telopeptide of type I collagen (CTX).
l Change in BMD: lumbar spine and total hip by dual-energy X-ray absorptiometry (DXA).
l Change in muscle function: short physical performance battery (SPPB) and hand grip strength. SPPB
score is a measure of lower limb strength and balance. It predicts falls, loss of function in activities
of daily living, nursing home admission and mortality.36–38
l Change in anti-oxidant activity: glutathione peroxidase activity (a selenium-containing anti-oxidant
that is increased in postmenopausal women with osteopenia).17
l Change in inflammatory markers: the pro-resorptive inflammatory cytokine IL-6 and highly sensitive
C-reactive protein (hsCRP).
The study was approved by Yorkshire and the Humber Research Ethics Committee (REC reference
16/YH/0393). All participants gave written informed consent, and the study was conducted in accordance
with the declaration of Helsinki. Potential participants were identified from a database of previous study
volunteers, patients attending the Sheffield Metabolic Bone Centre for fracture risk assessment, and
through poster and e-mail publicity. The trial was supervised by a Trial Steering Committee (TSC) and a
Data Monitoring Committee (DMC). The committees had independent membership, each including bone
and diabetes specialist physicians and a statistician. They approved the protocol and statistical analysis
plan (SAP) and met every 6 months during the trial. The DMC had access to serious adverse event (SAE)
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in NTX is associated with a 40% reduction in spine fracture, and 66% of the vertebral fracture risk
information and unblinded data, and reported to the TSC. Committee reports were uploaded to the NIHR
monitoring team.
This was a single-centre trial in Sheffield, UK. Participants were recruited between January 2017 and
April 2018 from a database of volunteers, poster and e-mail advertising, and patients attending the
metabolic bone centre for bone densitometry.
The inclusion criteria were women:
l aged > 55 years, and at least 5 years since last menstrual period
l with osteopenia or osteoporosis (DXA BMD lowest T-score between –1.0 and –3.0 at lumbar spine
or total hip), who did not require pharmacological treatment for fracture prevention
l willing and able to give informed consent.
The exclusion criteria were:
l diabetes mellitus
l thyroid dysfunction [history of hyper- or hypothyroidism, or thyroid-stimulating hormone (TSH)
outside the local reference range]
l any conditions known to affect bone metabolism, such as inflammatory disease, parathyroid disease,
malabsorption, high alcohol intake (> 21 units per week) and prolonged immobility
l fracture or orthopaedic surgery in the past year
l osteoporosis treatment or drugs known to affect bone metabolism in the past year
l selenium supplements in the past 60 days
l previous adverse reaction to selenium or any of the Investigational Medical Product (IMP) or
placebo excipients.
Women taking calcium and vitamin D supplements were not excluded as long as they had been
taking the calcium and vitamin D for at least 60 days and planned to continue throughout the trial.
All participants were given a single oral dose of 100,000 IU colecalciferol at screening to ensure
that they were vitamin D sufficient at the start of trial treatment.
We did not set inclusion/exclusion criteria based on serum selenium status because it was important
that the results of this study were generalisable into practice. However, we specified that only women
with baseline serum selenium < 120 µg/l would be included in the primary analysis.
The study had 90% power to detect a 20% between-group difference at the 2.5% (two-sided) level
[approximately 10 nmol bone collagen equivalents (BCE)/mmolCr] in NTX/Cr.
We determined 20% as a plausible effect size, based on estimated change in serum selenium and the
regression co-efficient of serum selenium and NTX/Cr in our previous study. We did not expect as
large a change in bone turnover as in a potent anti-resorptive drug such as a bisphosphonate, but it
might be similar to a weaker anti-resorptive such as a selective oestrogen receptor modulator (SERM).
In a study of 6 months of treatment with the SERM lasofoxifene in 51 postmenopausal women,39
NTX/Cr decreased by 29%. We also used this study to estimate the standard deviation (SD)
(12.5 nmol BCE/mmolCr) and the correlation between NTX/Cr at baseline and 6 months (0.7).
A 20% decrease in NTX is clinically significant; a 20% decrease in NTX (about 1 SD decrease) with
bisphosphonate treatment is associated with a 30% decrease in incident vertebral fracture.40
The sample size was calculated using the pwr library41 in R (The R Foundation for Statistical
Computing, Vienna, Austria).
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Assuming a SD of 12.5, and a significant difference of 10 nmol BCE/mmolCr, to achieve 90% power
to detect this difference at the 0.025% (two-sided) level would require 41 patients per group.
The primary analysis was an analysis of covariance, and, having assumed that the correlation between
NTX/Cr at baseline and 26 weeks was 0.7, 21 patients per group were required.42 To allow for dropout,
group imbalance, estimated number of participants with serum selenium > 120 µg/l and the secondary
end-point analyses, we recruited 40 patients per group.
Participants were block randomised equally to the three intervention arms. The randomisation list was
generated by Sharp Clinical, and the IMP packs were delivered to the study site labelled by randomisation
number. Participants were given the IMP pack labelled with their randomisation number.
We included an interim analysis of baseline serum selenium after the first 40 participants were recruited,
with a plan to increase the sample size if many women had serum selenium > 120 µg/l. The only data
reviewed were blinded baseline serum selenium. The final minimum sample size was determined as
follows: (100/number of participants with baseline serum < 120 µg/l) × 40. The outcome of the interim
analysis was planned as follows:
l If the minimum sample size is < 120, a target sample size of 120 will be maintained.
l If the minimum sample size is 121–165, the target sample size will be increased accordingly. If the
number of participants with baseline serum selenium > 120 µg/l could be high enough to suggest
significant group imbalance in the final primary end-point analysis, the DMC will consider whether
stratification for baseline serum selenium should be introduced for subsequent randomisation.
l If the minimum sample size is > 165, the DMC will consider whether or not the trial should
continue and make a recommendation to the TSC.
All of the first 40 participants had baseline serum selenium < 120 µg/l, so we maintained the original
recruitment target of 120 participants. We conducted a secondary analysis of all participants to
determine whether or not baseline serum selenium was a determinant of bone turnover response.
Statistics
A detailed SAP was developed and approved by the TSC prior to locking the trial database. We
conducted an intention-to-treat (ITT) analysis (all randomised participants) and per-protocol analysis.
The per-protocol analysis included completing participants who took at least 75% of IMP, which was
assessed by reported missed doses and returned tablet count.
Baseline data were assessed for comparability between the treatment groups. The normality of either
the raw data or the residuals from the model using a density plot or histogram was assessed.
Primary end point: urine NTX/Cr at 26 weeks
An analysis of covariance was used with 26-week NTX/Cr measurement as the dependent outcome
variable, and treatment group and baseline NTX/Cr measurement as the independent variable.
The residuals from the model were not normally distributed, so NTX/Cr was log-transformed and
the treatment group differences were back-transformed so that they could be presented as a ratio.
The statistical analysis plan prespecified a Hochberg testing procedure that allows an investigation
into the three treatment arms to take place while maintaining the overall type I error rate at 5%.
This stated that significance would be declared for a comparison between placebo and selenium if
and only if both selenium doses were significant at the 5% level or if either dose was significant at the
2.5% level. If and only if significance was declared for both selenium doses, a comparison would be
made between the doses. A comparison between 200 µg selenium and 50 µg selenium would be made
at the 5% level of significance.
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We examined the impact of baseline selenium levels on the NTX response to selenium
supplementation by fitting a linear model with NTX at follow-up as the dependent variable and
baseline selenium, baseline NTX and dose as independent variables.
The statistical analysis plan prespecified a multiple imputation strategy with 20 imputations utilising
baseline and week 13 measurements of NTX/Cr, age of patient and treatment allocation. It also
specified that additional variables associated with missing data would also be included in the multiple
imputation model to make the missing-at-random assumption as plausible as possible. The nature of
missingness and other baseline variables was explored in relation to missing data on the primary end
point using univariable logistic regression models. The only baseline variable predictive of missingness
was body mass index (BMI). The final multiple imputation model therefore utilised baseline and
week 13 measurements of NTX/Cr, age of patient, BMI of patient at baseline and treatment allocation.
The results using the imputation model did not differ from those for the ITT population.
Secondary end points
Urine NTX at 13 weeks and BMD by DXA at 26 weeks were analysed, as described for the primary
end point.
All other secondary end-point measurements at 13 and 26 weeks were compared between treatment
groups using linear mixed models with a random intercept to allow multiple measurements on individuals.
The models included fixed factors for treatment group and post-randomisation time, and a covariate
for the baseline measurement of the outcome. To determine if the effect of treatment changed with
time, an interaction between treatment group and time was tested. If this interaction was not
statistically significant, then it was removed from the model and the overall treatment difference was
reported. If there was a significant difference between treatment groups, the pairwise comparisons
were made between each treatment group and the placebo group and the two doses were compared.
Efficacy measurements
Blood samples for biochemical measurements were taken fasted in the morning. Serum samples were
obtained in serum-separating tubes, allowed to clot for 30 minutes and then centrifuged at 2500 r.p.m.
for 10 minutes and separated into aliquots.
Urine samples were obtained as triplicate samples from fasted second morning voids on each of the
3 days before the study visit, or on the 2 days before and the day of the study visit. Equal volume
aliquots from the urine samples were pooled into a single sample by the study team, then the pooled
sample was separated into aliquots.
Samples were frozen at –80 °C and analysed in batches at the end of the study.
Urine NTX was measured by automated immunoassay (Vitros ECiQ, Ortho Clincal Diagnostics, High
Wycombe, UK) at PathLab London [interassay coefficient of variation (CV) 6%]. NTX was expressed
as a ratio to urinary creatinine concentration measured by the dry slide method (Vitros 250, Ortho
Clinical Diagnostics, interassay CV 3%).
Serum selenium was measured by X-ray fluorescence spectroscopy,43 SePP was measured by
immunoassay,44 and glutathione peroxidase was measured by an enzyme analysis by Professor
Lutz Schomburg, Institute for Experimental Endocrinology, Charité – University Medical School Berlin.
METHODS
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CTX, OC, PINP and 25OHD (25-hydroxyvitamin D) were measured by automated immunoassay
(IDS-iSYS, Immunodiagnostic Systems, Boldon, UK) by the University of Sheffield Academic Unit of
Bone Metabolism. The interassay CVs are 6.5, 5.0, 7.2 and 6.7%, respectively.
IL-6 and hsCRP were measured by automated immunoassay by the Sheffield Teaching Hospitals
Clinical Immunology Laboratory.
Height and weight were measured with an electric scale and stadiometer to the nearest 0.1 cm and
0.1 kg. Pulse and blood pressure were measured with an automated sphygmomanometer (Dinamap™,
GE Healthcare, Chalfont St Giles, UK).
Grip strength was assessed using a digital hand dynamometer (Saehan Corporation, Masan, Republic of Korea).
Three measurements were taken for each hand, and the best value was used for analysis.
The SPPB score was calculated from a chair stand and narrow walk test.36
BMD was assessed using DXA of the spine and hip (Hologic DIscovery, Hologic Inc., Marlborough, MA, USA)
at baseline and at 6 months, in accordance with standard scanning protocols, by specialist DXA scan
technicians in the Sheffield Clinical Research Facility.
Dietary selenium and other nutrient intakes were assessed with 7-day diet diaries. The purpose of
the food diaries was to describe participants’ habitual dietary intake of selenium and nutrients that
influence bone turnover. The diaries were analysed using DIETQ (Tinuviel Software, Warrington, UK)
by a nutritionist with experience in clinical research.
Safety measurements
Safety assessments for diabetes and thyroid function were made at screening (non-fasted), baseline,
13 weeks and 26 weeks. The measurements were made in real time by Sheffield Teaching Hospitals
pathology laboratories. Participants with parameters outside the reference range were withdrawn from
treatment and followed up as ITT.
Adverse events (including questioning for possible symptoms of selenium toxicity) were collected from
the time of consent, at study visits and by monthly telephone contact throughout the treatment period




We intended to measure hydroperoxidases as a marker of reactive oxygen species, but the commercially
available assay was withdrawn before completion of the study.
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• Interested, n = 207 (43%)
• Not interested, n = 75 (16%)
• No reply, n = 198 (41%)
Reason for ineligibility
(n = 2133)
• BMD too high/low, n = 1161 (54%)
• Disease/drug affecting bone, n = 690 (32%)
• Diabetes or thyroid, n = 207 (10%)
• Recent fracture, n = 59 (3%)
• Social/frailty/dementia, n = 16 (1%)
Selenase 200 µg
(n = 40)
• Participant withdrew, n = 1
• Stopped treatment (AE), n = 0
• Stopped treatment (TSH), n = 1
• Stopped treatment (glucose), n = 0
• Compliance < 75%, n = 5
Selenase 50 µg
(n = 40)
• Participant withdrew, n = 1
• Stopped treatment (AE), n = 1
• Stopped treatment (TSH), n = 3
• Stopped treatment (glucose), n = 1
• Compliance < 75%, n = 3
Placebo
(n = 40)
• Participant withdrew, n = 3
• Stopped treatment (AE), n = 1
• Stopped treatment (TSH), n = 3
• Stopped treatment (glucose), n = 0






• BMD too high/low, n = 48 (72%)
• Blood sugar or TSH abnormal, n = 14 (20%)
• Withdrew after screening, n = 3 (4%)
• Other, n = 2 (3%)
FIGURE 1 The CONSORT (Consolidated Standards of Reporting Trials) flow diagram. PP, per protocol.
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The participants’ baseline characteristics are shown in Tables 1–3. The groups were generally well
balanced, and the mean baseline serum selenium was 79.4 µg/l. All participants had baseline serum
selenium < 120 µg/l and so were included in the primary analysis.
Nine participants had missing data for baseline or week 26 NTX/Cr, so 106 were included in the
primary end-point analysis. Baseline characteristics for participants with and participants without
complete primary end-point data were similar.
The sample size calculation assumed a correlation between baseline and week 26 NTX/Cr
measurement of 0.7. In the ITT population, the Pearson correlation between baseline and week 26
NTX/Cr was 0.62 [95% confidence interval (CI) 0.49 to 0.73]. The residuals from the model were not
normally distributed, so NTX/Cr was log-transformed and the treatment group differences were
back-transformed so that they could be presented as a ratio.







(n= 39) Placebo (n= 37) All (N= 115)
Age (years) Mean (SD) 66.7 (6.1) 64.5 (6.1) 66.6 (6.0) 65.9 (6.1)
Range 56.0 to 79.0 55.0 to 77.0 56.0 to 83.0 55.0 to 83.0
Height (cm) Mean (SD) 162.0 (6.4) 161.5 (7.9) 160.6 (5.7) 161.4 (6.7)
Range 147.1 to 174.3 147.4 to 176.9 144.0 to 170.2 144.0 to 176.9
Weight (kg) Mean (SD) 65.5 (9.2) 66.9 (10.8) 65.7 (11.2) 66.0 (10.4)
Range 45.3 to 85.5 47.3 to 96.8 47.2 to 85.7 45.3 to 96.8
SPPB (score/12) Median (IQR) 11.0 (10.0 to 11.5) 10.0 (9.0 to 11.0) 11.0 (9.0 to 11.0) 11.0 (9.0 to 11.0)
Range 5.0 to 12.0 6.0 to 12.0 7.0 to 12.0 5.0 to 12.0
Hand grip strength
dominant (kg)
Median (IQR) 19.9 (16.2 to 22.7) 19.2 (17.2 to 21.8) 19.1 (15.9 to 21.1) 19.2 (16.2 to 21.5)
Range 12.7 to 31.0 7.4 to 34.9 10.4 to 27.9 7.4 to 34.9
Systolic BP (mmHg) Mean (SD) 132 (18) 132 (18) 131 (22) 132 (19)
Range 104 to 169 108 to 176 97 to 186 97 to 186
Diastolic BP (mmHg) Mean (SD) 68 (8) 71 (10) 72 (12) 70 (10)
Range 56 to 89 54 to 94 51 to 97 51 to 97
Glucose (mmol/l) Mean (SD) 5.2 (1.0) 5.1 (0.6) 5.0 (0.6) 5.1 (0.8)
Range 3.5 to 8.3 3.7 to 7.2 3.9 to 6.7 3.5 to 8.3
Insulin (pmol/l) Median (IQR) 49.8 (32.9 to 70.4) 48.7 (33.8 to 68.5) 44.7 (29.3 to 74.1) 47.0 (32.2 to 70.3)
Range 21.3 to 276.6 17.8 to 283.6 14.4 to 137.4 14.4 to 283.6
TSH (mIU/l) Mean (SD) 2.01 (0.94) 1.95 (0.89) 1.90 (0.87) 1.96 (0.89)
Range 0.70 to 4.20 0.64 to 3.60 0.87 to 4.20 0.64 to 4.20
HbA1c (mmol/mol) Mean (SD) 36.0 (2.5) 36.2 (2.4) 35.6 (2.3) 35.9 (2.4)
Range 30.0 to 42.0 31.0 to 43.0 32.0 to 41.0 30.0 to 43.0
25OHD (ng/ml) Mean (SD) 39.5 (12.1) 37.7 (12.7) 37.8 (10.8) 38.3 (11.8)
Range 16.9 to 70.0 19.1 to 68.6 17.7 to 62.8 16.9 to 70.0
BP, blood pressure; HbA1c, glycated haemoglobin; IQR, interquartile range.
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The primary end point (urine NTX/Cr) did not differ between treatment groups after 26 weeks or
13 weeks (Figures 2 and 3 and Table 4). Eighty-six participants were included in the per-protocol analysis,
and NTX/Cr did not differ between treatment groups after 26 weeks or 13 weeks (Table 5).
Mean serum selenium increased from baseline to 26 weeks in the treatment groups; 78.8 µg/l (95% CI
73.5 to 84.2 µg/l) to 105.7 µg/l (95%CI 99.5 to 111.9 µg/l) in the 200 µg group, and 79.3 µg/l (95% CI
74.2 to 84.4 µg/l) to 96.2 µg/l (95% CI 90.7 to 101.6 µg/l) in the 50 µg group. There was no change in
the placebo group (Table 6 and Figure 4). Mean serum SePP increased from baseline to 26 weeks in
the treatment groups; 5.15 mg/l (95% CI 4.71 to 5.60 mg/l) to 6.03 mg/l (95% CI 5.54 to 6.51 mg/l)
in the 200 µg group and 5.21 mg/l (95% CI 4.73 to 5.70 mg/l) to 6.25 mg/l (95% CI 5.79 to 6.70 mg/l)
in the 50 µg group. There was no change in the placebo group (see Table 6 and Figure 5).
TABLE 2 Baseline selenium status, anti-oxidant and inflammatory markers by treatment group
Variable
Summary
statistic Selenase 50 µg Selenase 200 µg Placebo All
Serum selenium
(µg/l)
Mean (SD) 79.3 (15.6) 78.8 (16.5) 80.2 (14.2) 79.4 (15.3)
Range 43.2 to 108.9 35.1 to 110.6 49.4 to 116.5 35.1 to 116.5
SePP (mg/l) Mean (SD) 5.21 (1.47) 5.15 (1.37) 5.22 (1.45) 5.19 (1.42)












Range 20.2 to 435.0 21.8 to 334.3 12.7 to 387.5 12.7 to 435.0
hsCRP (mg/) Median (IQR) 0.75 (0.41 to 1.29) 0.94 (0.41 to 1.75) 1.29 (0.47 to 2.40) 0.95 (0.45 to 1.85)
Range 0.15 to 24.70 0.15 to 40.10 0.15 to 7.14 0.15 to 40.10
IL-6 (ng/l) Median (IQR) 1.0 (1.0 to 1.7) 1.0 (1.0 to 2.2) 1.0 (1.0 to 1.7) 1.0 (1.0 to 1.8)
Range 1.0 to 14.8 1.0 to 23.2 1.0 to 6.8 1.0 to 23.2
IQR, interquartile range.







(n= 39) Placebo (n= 37) All (n= 115)
Lumbar spine BMD
(T-score)
Mean (SD) –1.8 (1.0) –1.8 (0.6) –1.7 (0.9) –1.8 (0.8)
Range –2.9 to 0.7 –3.0 to –0.2 –3.1 to 2.0 –3.1 to 2.0
Total hip BMD
(T-score)
Mean (SD) –1.2 (0.7) –0.9 (0.6) –1.3 (0.7) –1.1 (0.7)
Range –2.3 to 1.3 –2.4 to 0.6 –2.7 to 0.5 –2.7 to 1.3
NTX/Cr
(nmolBCE/mmol)
Median (IQR) 38.2 (33.7 to 49.7) 42.0 (35.0 to 49.5) 37.5 (29.7 to 49.1) 38.2 (31.4 to 49.7)
Range 19.4 to 70.8 20.2 to 103.4 16.3 to 124.1 16.3 to 124.1
PINP (µg/l) Median (IQR) 50.1 (37.5 to 68.6) 49.6 (39.9 to 62.3) 49.8 (38.7 to 60.0) 49.8 (38.9 to 62.3)
Range 23.1 to 96.1 23.3 to 98.6 27.5 to 105.7 23.1 to 105.7
IQR, interquartile range.
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A linear regression model was fitted with log(week 26 NTX/Cr) as the dependent variable and log
(baseline NTX/Cr), baseline selenium and treatment group as the independent variables. The interaction
between treatment group and baseline selenium was not statistically significant (p = 0.465), suggesting
that treatment group did not modify the relationship between baseline selenium and week 26 NTX/Cr.
There were no differences between treatment groups in any of the other biochemical markers of bone
turnover (PINP, CTX or OC) at 26 weeks or 13 weeks (Table 7).
There was a small statistically significant but not clinically relevant difference in lumbar spine BMD
T-score at 26 weeks in the 50 µg group (T-score difference 0.2) compared with the placebo group and
the 200 µg group (T-score difference –0.1). Total hip BMD did not differ between treatment groups at
26 weeks (Table 8).
There was a statistically significant but small (0.5/12) unfavourable difference in the SPPB score in
the 50 µg group compared with the placebo group at 26 weeks, but there was no difference between
the 200 µg group and the placebo group; overall, there was no significant treatment effect (p = 0.08).
























































FIGURE 3 NTX/Cr 13 weeks: ITT analysis.
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TABLE 4 NTX/Cr by treatment group at 26 weeks and 13 weeks (ITT analysis)
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Ratiob (95% CI) p-value Ratiob (95% CI) p-value Ratiob (95% CI) p-value
NTX/Cr (nmolBCE/mmol) (primary outcome)
Baseline 34 37.7 (32.5 to 43.6) 35 40.1 (35.9 to 44.8) 37 41.9 (37.0 to 47.4) – – – – – –
26 weeks 34 40.5 (34.9 to 47.0) 35 43.4 (37.4 to 50.5) 37 42.2 (37.5 to 47.6) 1.03 (0.88 to 1.19) 0.737 0.97 (0.83 to 1.12) 0.658 0.94 (0.81 to 1.09) 0.429
NTX/Cr (nmolBCE/mmol) (secondary outcome)
Baseline 35 37.6 (32.6 to 43.3) 36 40.2 (36.1 to 44.7) 39 42.2 (37.5 to 47.6) – – – – – –
13 weeks 35 39.7 (34.4 to 45.8) 36 42.0 (37.3 to 47.3) 39 43.1 (39.0 to 47.7) 1.01 (0.90 to 1.13) 0.881 1.00 (0.89 to 1.12) 0.988 0.99 (0.89 to 1.11) 0.890
a Geometric mean and 95% CI.
b Ratio of means for treatment group from ANCOVA model adjusting for baseline measurement. Outcome variable was log-transformed and the treatment group difference was
back-transformed to give a ratio.
TABLE 5 NTX/Cr by treatment group at 26 weeks and 13 weeks (per-protocol analysis)
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Ratiob (95% CI) p-value Ratiob (95% CI) p-value Ratiob (95% CI) p-value
NTX/Cr (nmolBCE/mmol) (primary outcome)
Baseline 25 37.4 (31.8 to 44.0) 29 41.0 (36.2 to 46.5) 32 40.9 (36.0 to 46.6) – – – – – –
26 weeks 25 42.4 (35.2 to 51.1) 29 44.3 (37.6 to 52.3) 32 40.6 (35.7 to 46.1) 0.98 (0.82 to 1.17) 0.803 0.90 (0.76 to 1.06) 0.210 0.92 (0.78 to 1.08) 0.294
NTX/Cr (nmolBCE/mmol) (secondary outcome)
Baseline 25 37.4 (31.8 to 44.0) 28 41.7 (36.8 to 47.2) 33 40.8 (36.0 to 46.3) – – – – – –
13 weeks 25 41.2 (35.8 to 47.5) 28 43.4 (37.9 to 49.7) 33 42.3 (38.2 to 46.9) 0.98 (0.86 to 1.12) 0.766 0.97 (0.86 to 1.10) 0.619 0.99 (0.88 to 1.11) 0.845
a Geometric mean and 95% CI.
b Ratio of means for treatment group from the analysis of covariance model adjusting for baseline measurement. Outcome variable was log-transformed and the treatment group




























































































































































































































































































































































































































































































TABLE 6 Serum selenium and SePP by treatment group at 13 weeks and 26 weeks
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Differenceb (95% CI) p-value Differenceb (95% CI) p-value Differenceb (95% CI) p-value
Serum selenium (µg/l)
Baseline 37 80.2 (75.5 to 85.0) 38 79.3 (74.2 to 84.4) 39 78.8 (73.5 to 84.2) – – – – – –




– – – – – –




20.5 (14.5 to 26.5) < 0.001 27.5 (21.6 to 33.4) < 0.001 7.0 (1.1 to 12.8) 0.020
SePP (mg/l)
Baseline 37 5.22 (4.73 to 5.70) 38 5.21 (4.73 to 5.70) 39 5.15 (4.71 to 5.60) – – – – – –
13 weeks 37 5.50 (5.11 to 5.91) 37 6.85 (6.24 to 7.46) 38 6.47 (5.89 to 7.04) – – – – – –
26 weeks 33 5.31 (4.75 to 5.87) 37 6.25 (5.79 to 6.70) 39 6.03 (5.54 to 6.51) 1.17 (0.62 to 1.72) < 0.001 0.88 (0.34 to 1.42) 0.002 –0.29 (–0.83 to 0.25) 0.287
a Arithmetic mean and 95% CI.




































Measurements of anti-oxidant activity and inflammation did not differ between treatment groups (Table 10).
The majority of IL-6 measurements were below the limit of detection of 1.6 ng/l (74/110 at baseline, 71/110
at week 13 and 74/108 at week 26), so no further analysis was conducted on the IL-6 measurements.
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FIGURE 5 Serum SePP by treatment group at 13 weeks and 26 weeks.
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FIGURE 4 Serum selenium by treatment group at 13 weeks and 26 weeks.
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TABLE 7 Biochemical markers of bone turnover by treatment group at 13 weeks and 26 weeks
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Ratiob (95% CI) p-value Ratiob (95% CI) p-value Ratiob (95% CI) p-value
PINP (µg/l)
Baseline 37 48.2 (43.3 to 53.6) 38 50.2 (44.6 to 56.5) 39 49.6 (44.5 to 55.4) – – – – – –
13 weeks 36 46.1 (41.5 to 51.3) 37 49.9 (44.0 to 56.7) 39 49.6 (44.0 to 56.0) – – – – – –
26 weeks 34 47.0 (42.5 to 52.0) 37 46.8 (41.0 to 53.3) 37 47.0 (41.3 to 53.6) 0.97 (0.91 to 1.04) 0.381 0.99 (0.93 to 1.06) 0.816 1.02 (0.96 to 1.09) 0.508
OC (µg/l)
Baseline 37 15.7 (13.4 to 18.4) 38 14.8 (12.7 to 17.2) 39 15.7 (13.8 to 17.9) – – – – – –
13 weeks 36 14.0 (12.2 to 16.1) 37 15.7 (13.8 to 17.9) 39 15.0 (13.3 to 17.0) – – – – – –
26 weeks 34 14.4 (12.6 to 16.4) 37 14.1 (12.3 to 16.2) 37 13.9 (12.4 to 15.6) 1.07 (0.95 to 1.21) 0.343 1.01 (0.89 to 1.15) 0.848 0.95 (0.84 to 1.08) 0.439
CTX (µg/l)
Baseline 37 0.15 (0.11 to 0.22) 38 0.14 (0.10 to 0.19) 39 0.15 (0.12 to 0.21) – – – – – –
13 weeks 35 0.13 (0.10 to 0.17) 36 0.15 (0.11 to 0.21) 37 0.13 (0.10 to 0.18) – – – – – –
26 weeks 34 0.13 (0.09 to 0.17) 37 0.12 (0.09 to 0.16) 37 0.11 (0.09 to 0.15) 1.07 (0.80 to 1.45) 0.656 0.97 (0.72 to 1.30) 0.811 0.90 (0.67 to 1.20) 0.470
a Geometric mean and 95% CI.
b Ratio of means for treatment group from the mixed effects model adjusting for baseline measurement. Outcome variable was log-transformed and the treatment group difference




































TABLE 8 Lumbar spine and total hip BMD by treatment group at 26 weeks
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Differenceb (95% CI) p-value Differenceb (95% CI) p-value Differenceb (95% CI) p-value
DXA T-score total hip
Baseline 34 –1.3 (–1.5 to –1.0) 38 –1.2 (–1.5 to –1.0) 39 –0.9 (–1.1 to –0.7) – – – – – –
26 weeks 34 –1.2 (–1.5 to –1.0) 38 –1.2 (–1.4 to –1.0) 39 –0.9 (–1.1 to –0.7) (–0.1 to 0.1) 0.954 0.0 (–0.1 to 0.1) 0.958 0.0 (–0.1 to 0.1) 0.911
DXA T-score lumbar spine
Baseline 34 –1.7 (–2.0 to –1.4) 37 –1.9 (–2.2 to –1.6) 37 –1.8 (–2.0 to –1.6) – – – – – –
26 weeks 34 –1.8 (–2.1 to –1.5) 37 –1.8 (–2.1 to –1.5) 37 –1.9 (–2.1 to –1.7) 0.2 (0.0 to 0.3) 0.013 0.2 (–0.1 to 0.1) 0.802 –0.1 (–0.3 to 0.0) 0.021
a Arithmetic mean and 95% CI.




























































































































































































































































































































































































































































































TABLE 9 Physical function tests by treatment group at 13 weeks and 26 weeks
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Differenceb (95% CI) p-value Differenceb (95% CI) p-value Differenceb (95% CI) p-value
SPPB (score/12)
Baseline 37 10.2 (9.7 to 10.7) 39 10.3 (9.7 to 10.9) 39 10.0 (9.6 to 10.5) – – – – – –
13 weeks 37 10.8 (10.5 to 11.3) 39 10.3 (9.8 to 10.8) 39 10.4 (9.7 to 11.0) – – – – – –
26 weeks 36 10.9 (10.5 to 11.4) 38 10.4 (9.9 to 10.9) 39 10.3 (9.7 to 10.8) –0.5 (–1.1 to –0.03) 0.037 –0.5 (–1.0 to 0.05) 0.074 0.1 (–0.4 to 0.6) 0.759
Grip strength dominant hand (kg)
Baseline 37 18.6 (17.3 to 20.0) 39 19.8 (18.3 to 21.3) 39 19.5 (17.9 to 21.1) – – – – – –
13 weeks 37 18.6 (17.3 to 20.0) 39 19.4 (18.0 to 20.8) 39 19.2 (17.9 to 20.5) – – – – – –
26 weeks 36 18.1 (16.6 to 19.5) 36 18.9 (17.4 to 20.4) 39 18.4 (16.9 to 19.8) –0.3 (–1.2 to 0.6) 0.490 –0.3 (–1.2 to 0.6) 0.497 0.01 (–0.9 to 0.9) 0.987
Grip strength non-dominant hand (kg)
Baseline 37 16.8 (15.5 to 18.2) 38 18.1 (16.8 to 19.3) 38 17.6 (16.3 to 18.9) – – – – – –
13 weeks 37 17.1 (15.8 to 18.4) 37 17.2 (16.0 to 18.4) 38 17.3 (15.7 to 18.8) – – – – – –
26 weeks 36 16.1 (14.7 to 17.5) 36 17.0 (15.8 to 18.2) 38 16.7 (15.1 to 18.3) –0.7 (–1.6 to 0.2) 0.131 –0.3 (–1.2 to 0.6) 0.589 0.4 (–0.5 to 1.3) 0.402
a Arithmetic mean and 95% CI.




































TABLE 10 Anti-oxidant activity and inflammation by treatment group at 13 weeks and 26 weeks
Time
point















– – – – – –






– – – – – –






10.1 (–17.5 to 37.8) 0.470 –8.8 (–36.1 to 18.6) 0.527 –18.9 (–45.9 to 8.1) 0.169
hsCRP (mg/l)c,d
Baseline 36 1.14 (0.80 to 1.63) 35 0.80 (0.55 to 1.15) 38 1.00 (0.65 to 1.41) – – – – – –
13 weeks 36 1.12 (0.75 to 1.65) 35 0.77 (0.55 to 1.08) 38 1.04 (0.78 to 1.38) – – – – – –
26 weeks 35 1.31 (0.88 to 1.94) 33 0.81 (0.58 to 1.13) 37 1.09 (0.74 to 1.60) 0.84 (0.63 to 1.15) 0.282 0.99 (0.74 to 1.32) 0.933 1.17 (0.87 to 1.57) 0.310
GPx, glutathione peroxidase.
a Arithmetic mean and 95% CI.
b Difference in means for treatment group from the mixed-effects model, adjusting for baseline measurement.
c Geometric mean and 95% CI.
d Ratio of means for treatment group from the mixed-effects model, adjusting for baseline measurement. Outcome variable was log-transformed and the treatment group difference




























































































































































































































































































































































































































































































The safety assessments for diabetes and thyroid function did not differ between treatment groups.
There was a small difference in glycated haemoglobin (HbA1c) between 200 µg and placebo groups at
26 weeks (–1.0 mmol/mol), but this is not clinically significant (Table 11). Seven participants were
withdrawn from treatment at week 13 because of abnormal TSH (200 µg, n = 1; 50 µg, n = 3; placebo,
n = 3), and one was withdrawn because of abnormal blood glucose (in the 50 µg group).
Analyses were repeated in the per-protocol group for all efficacy and safety end points, and the results
did not differ from those for the ITT population.
The study group were generally vitamin D replete. There was a small difference in 25OHD between
200 µg and placebo groups at 26 weeks, but this is not clinically significant (Table 12).
The dietary intake of vitamin D, calcium and selenium assessed by a 7-day diet diary were similar in
all three treatment groups (Table 13). The dietary selenium intake decreased between baseline and
26 weeks in all three groups.
The number and severity of adverse events and the systems affected by adverse events were similar
across treatment groups (Tables 14 and 15).
There were three serious adverse events: a non-ST elevation myocardial infarction at week 18 (in the
50 µg/day group); a diagnosis of bowel cancer after routine screening at week 2 (in the placebo group);
and a pulmonary embolus due to metastatic bowel cancer at week 4 (in the 200 µg/day group). All SAEs
were judged by the principal investigator as unrelated to trial medication.
RESULTS
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TABLE 11 Diabetes and thyroid function by treatment group at 13 weeks and 26 weeks
Time
point







n Mean (95% CI) n Mean (95% CI) n Mean (95% CI) Difference (95% CI) p-value Difference (95% CI) p-value Difference (95% CI) p-value
Fasting blood glucose (mmol/l)a,b
Baseline 37 5.0 (4.8 to 5.2) 39 5.2 (4.9 to 5.5) 38 5.1 (4.9 to 5.3) – – – – – –
13 weeks 37 4.9 (4.6 to 5.1) 37 5.1 (4.9 to 5.3) 37 4.9 (4.7 to 5.1) – – – – – –
26 weeks 36 4.9 (4.7 to 5.1) 38 4.9 (4.9 to 5.1) 38 4.9 (4.8 to 5.1) 0.2 (–0.1 to 0.4) 0.150 0.04 (–0.2 to 0.3) 0.709 –0.1 (–0.4 to 0.1) 0.280
Insulin (pmol/l)c,d
Baseline 33 46.3 (37.4 to 57.4) 33 52.7 (41.8 to 66.6) 36 51.6 (41.8 to 63.7) – – – – – –
13 weeks 32 46.0 (36.5 to 57.9) 31 54.0 (43.2 to 67.6) 35 55.5 (43.3 to 71.2) – – – – – –
26 weeks 33 46.8 (38.3 to 57.2) 32 46.4 (37.7 to 57.1) 35 47.3 (38.8 to 57.6) 0.99 (0.82 to 1.21) 0.944 1.05 (0.87 to 1.27) 0.624 1.06 (0.87 to 1.28) 0.575
HbA1c (mmol/mol)
a,b
Baseline 37 35.6 (34.8 to 36.4) 39 36.0 (35.2 to 36.8) 39 36.2 (35.4 to 36.9) – – – – – –
13 weeks 36 36.9 (34.9 to 38.9) 37 36.6 (35.8 to 37.3) 38 35.7 (34.8 to 36.6) – – – – – –
26 weeks 36 36.3 (35.5 to 37.0) 38 36.6 (35.9 to 37.4) 37 36.1 (35.2 to 37.0) –0.3 (–1.3 to 0.6) 0.480 –1.0 (–2.0 to –0.1) 0.028 –0.7 (–1.6 to 0.2) 0.128
TSH (mIU/l)c,d
Baseline 37 1.74 (1.51 to 2.00) 39 1.80 (1.55 to 2.11) 39 1.74 (1.48 to 2.04) – – – – – –
13 weeks 36 2.19 (1.86 to 2.58) 37 2.41 (2.05 to 2.82) 36 2.31 (1.91 to 2.80) – – – – – –
26 weeks 36 2.39 (2.04 to 2.81) 39 2.19 (1.87 to 2.57) 39 2.22 (1.84 to 2.69) 0.96 (0.84 to 1.10) 0.568 0.97 (0.85 to 1.10) 0.682 1.01 (0.88 to 1.16) 0.870
a Arithmetic mean and 95% CI.
b Difference in means for treatment group from the mixed-effects model, adjusting for baseline measurement.
c Geometric mean and 95% CI.
d Ratio of means for treatment group from the mixed-effects model, adjusting for baseline measurement. Outcome variable was log-transformed and the treatment group difference




























































































































































































































































































































































































































































































TABLE 12 Serum vitamin D by treatment group at 13 weeks and 26 weeks
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Ratiob (95% CI) p-value Ratiob (95% CI) p-value Ratiob (95% CI) p-value
25OHD (ng/ml)
Baseline 37 36.3 (33.0 to 40.0) 38 37.7 (34.0 to 41.8) 39 35.8 (32.2 to 39.8) – – – – – –
13 weeks 37 33.1 (30.3 to 36.2) 37 34.6 (30.7 to 39.0) 39 30.9 (27.6 to 34.5) – – – – – –
26 weeks 36 32.5 (29.2 to 36.2) 37 31.9 (27.9 to 36.6) 39 29.4 (25.8 to 33.5) 0.98 (0.91 to 1.05) 0.485 0.93 (0.87 to 1.00) 0.041 0.96 (0.89 to 1.02) 0.176
a Geometric mean and 95% CI.
b Ratio of means for treatment group from the mixed-effects model, adjusting for baseline measurement. Outcome variable was log-transformed and the treatment group difference
was back-transformed to give a ratio.
TABLE 13 Dietary intake of vitamin D, selenium and calcium by treatment group at baseline and 26 weeks
Time
point







n Meana (95% CI) n Meana (95% CI) n Meana (95% CI) Ratiob (95% CI) p-value Ratiob (95% CI) p-value Ratiob (95% CI) p-value
Dietary vitamin D (µg/day)
Baseline 34 2.1 (1.5 to 2.8) 35 2.5 (2.0 to 3.0) 39 2.2 (1.8 to 2.8) – – – – – –
26 weeks 34 1.9 (1.4 to 2.6) 35 2.2 (1.8 to 2.8) 39 2.0 (1.8 to 2.8) 1.06 (0.78 to 1.44) 0.732 1.02 (0.75 to 1.37) 0.923 0.96 (0.71 to 1.30) 0.796
Dietary calcium (mg/day)
Baseline 34 769.9 (685.2 to 865.0) 35 850.7 (774.7 to 934.1) 39 795.5 (711.3 to 889.6) – – – – – –
26 weeks 34 740.3 (664.6 to 824.7) 35 829.0 (736.9 to 932.5) 39 688.9 (596.3 to 795.9) 1.03 (0.91 to 1.18) 0.629 0.91 (0.78 to 1.03) 0.122 0.88 (0.78 to 1.00) 0.041
Dietary selenium (µg/day)
Baseline 34 78.7 (73.8 to 83.9) 34 79.6 (74.5 to 85.0) 39 76.9 (71.2 to 83.0) – – – – – –
26 weeks 34 40.6 (35.4 to 46.5) 34 39.4 (34.3 to 45.1) 39 35.5 (31.1 to 40.7) 0.96 (0.81 to 1.16) 0.682 0.89 (0.75 to 1.06) 0.189 0.92 (0.77 to 1.10) 0.372
a Geometric mean and 95% CI.
b Ratio of means for treatment group from the mixed-effects model, adjusting for baseline measurement. Outcome variable was log-transformed and the treatment group difference



























































All 34 23 (62.2) 34 27 (69.2) 27 17 (43.6%) 95 67 (58.3)
Infection and
infestation
10 9 (24.3) 8 8 (20.5) 10 7 (17.9) 28 24 (20.9)
Gastrointestinal 5 5 (13.5) 5 4 (10.3) 4 4 (10.3) 14 13 (11.3)
Musculoskeletal and
connective




7 6 (16.2) 1 1 (2.6) 1 1 (2.6) 9 8 (7.0)
Respiratory 3 2 (5.4) 2 2 (5.1) 2 1 (2.6) 7 5 (4.3)
Skin and
subcutaneous
1 1 (2.7) 3 3 (7.7) 2 2 (5.1) 6 6 (5.2)
Renal and urinary 1 1 (2.7) 2 2 (5.1) 2 2 (5.1) 5 5 (4.3)
Neurological 1 1 (2.7) 2 2 (5.1) 1 1 (2.6) 4 4 (3.5)
Surgical and medical
procedures
1 1 (2.7) 2 2 (5.1) 0 0 (0.0) 3 3 (2.6)
Vascular 0 0 (0.0) 3 2 (5.1) 0 0 (0.0) 3 2 (1.7)
Eye 1 1 (2.7) 0 0 (0.0) 0 0 (0.0) 1 1 (0.9)
General 0 0 (0.0) 0 0 (0.0) 1 1 (2.6) 1 1 (0.9)
Neoplasms 1 1 (2.7) 0 0 (0.0) 1 1 (2.7) 2 2 (1.8)
Psychiatric 0 0 (0.0) 0 0 (0.0) 1 1 (2.6) 1 1 (0.9)























All 34 23 (62.2) 34 27 (69.2) 27 17 (43.6) 95 67 (58.3)
Grade 1 22 16 (43.2) 23 20 (51.3) 22 15 (38.5) 67 51 (44.3)
Grade 2 11 9 (24.3) 11 9 (23.1) 5 4 (10.3) 27 22 (19.1)
Grade 3 1 1 (2.7) 0 0 (0.0) 0 0 (0.0) 1 1 (0.9)
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We have conducted a well-powered, randomised, double-blind, placebo-controlled study of theeffects of selenium supplementation on musculoskeletal health in postmenopausal women.
We found no effect on biochemical markers of bone turnover, BMD or physical function with Selenase
200 µg or 50 µg daily. None of the end-point results differed between the ITT analysis and the per-protocol
analysis. This is an important result because it is from the first randomised controlled trial of selenium
supplementation for musculoskeletal health, to our knowledge.
Serum selenium in the 200 µg treatment group increased from 80 µg/l to 105 µg/l. Mortality data
suggest that the optimum range for serum selenium is 120–150 µg/l. Although serum selenium did not
reach this range, based on the correlation of serum selenium and NTX/Cr in our previous study, an
increase of 30% should be enough to demonstrate some change in bone markers if there was any
effect. Biochemical markers of bone turnover are dynamic and respond to bone active agents within
a few weeks. For example, bone markers decrease by about 20% within 2 weeks of starting calcium
supplements.45 Selenium at 200 µg/day has been shown to be effective in Graves’ eye disease and
cancer prevention studies, so there is good evidence that this dose is high enough to be biologically
active in humans. It is possible that higher dose supplements would have an effect on bone, but there
was no dose–response effect across the two doses we studied. In addition, higher doses may increase
the risk of adverse effects.33
There was a small increase in lumbar spine BMD in the 50 µg group, but, in the absence of any effect
on bone turnover or any BMD effect in the 200 µg group, this is likely to be a spurious result.
There were enough promising epidemiological, observational and pre-clinical data to suggest that
selenium might have beneficial effects on musculoskeletal health.
Higher selenium status is associated with BMD in men in the Netherlands.22 Higher dietary selenium
intake is associated with lower hip fracture risk in older adults in the USA23 and higher BMD in
middle-aged and older adults in China46 and Europe.14,22 However, there was no association with
BMD in postmenopausal Turkish women.24
Lower serum selenium and dietary selenium are associated with lower muscle mass and poorer muscle
function in older adults.27,47–49
The proposed mechanism of action of selenium to reduce reactive oxygen species, and therefore
reduce the pro-resorptive drive to osteoclasts, was plausible. However, we saw no effect at all on
markers of bone resorption. It may be that selenium status is a marker for other factors acting on bone
health or that a single factor approach is ineffective and selenium is part of a more complex system
that is not yet fully characterised.
The population in this study was generally representative of postmenopausal women in the UK, in
terms of BMI, BMD, vitamin D status and calcium intake. Their dietary selenium intake at baseline was
higher than expected for the UK, but at 26 weeks it was more typical.50 We do not know if this is a
true change in dietary behaviour over the course of the study; we might speculate that participants
reduced their dietary selenium intake because they were receiving a supplement. However, selenium is
a ubiquitous nutrient, and it would be difficult to reduce it in isolation.
We studied women only, and it is possible that the effects of selenium on bone would be different in men.
However, postmenopausal women have higher bone resorption than men, and we hypothesised that
selenium could act particularly through one of the resorption pathways activated by oestrogen deficiency.
Therefore, in the absence of any effect in women, we do not think that an effect in men is likely.
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We conclude that selenium supplementation at these doses is not beneficial for musculoskeletal health
in postmenopausal women. Other trials have demonstrated benefit in cancer prevention, so selenium
may have benefits for human health. However, it is not likely to be effective for treatment of
osteoporosis and reduction in fracture risk.
DISCUSSION
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Chapter 5 Patient and public involvement
The Sheffield Lay Advisory Panel for Bone Research has contributed to this study. The panel wasestablished in 2009 and has made valuable contributions to these aspects of research in the Academic
Unit of Bone Metabolism since then. It has received training in research methods, research governance
and grant application processes. The panel was consulted about trial design and contributed to the grant
application, protocol and recruitment strategy.
The panel received updates on the study’s progress at its monthly meetings; during these meetings,
panel members had the opportunity to discuss the study with investigators and other members of the
study team.
Now that the study is complete, the Sheffield Lay Advisory Panel for Bone Research will write a lay
summary of the results, which will be sent to study participants and publicised through the University
of Sheffield, Sheffield Teaching Hospitals and the Royal Osteoporosis Society.
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Appendix 1 Trial flow chart
Patients attending for fracture risk assessment
Sheffield Metabolic Bone Centre
E-mail and poster adverts
Volunteer database
Academic Unit of Bone Metabolism



















(28 days after end
of treatment) 
Randomisation
Informed consent and screening
Baseline assessments
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Appendix 2 Schedule of procedures













Blood for DNA ✓
Serum selenium ✓ ✓ ✓













Diet diary ✓ ✓
Concomitant
medications





Safety bloodse ✓ ✓
Compliance check ✓ ✓ ✓ ✓ ✓ ✓
Adverse events ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
a DXA was carried out at screening for patients without a BMD measurement in the past 6 months and was not
repeated at baseline. For patients with a BMD measurement in the past 6 months, this measurement was used for
eligibility, and BMD was measured at baseline.
b Glucose, HbA1c, TSH, bone profile, creatinine (non-fasted).
c Selenium, SePP, PINP, OC, CTX, glutathione peroxidase, hsCRP, IL-6, 25OH vitamin D.
d NTX/Cr.
e At baseline: glucose and insulin. At 13 weeks and 26 weeks: glucose, insulin, HbA1c, TSH.
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